The “BASE” study, now published in The Lancet Rheumatology, found mortality & AESIs among SLE patients taking Benlysta similar to placebo.
Specifically, the study evaluated mortality and Adverse Events of Special Interest (AESIs) with intravenous Belimumab for adults with active, Autoantibody-positive Systemic lupus Erythematosus (BASE). This was a multicenter, double-blind, randomized, placebo-controlled, phase 4 trial with 4,000 participants in 33 countries.
You can read more about this study in .